Polatuzumab vedotin (Polivy®). HTA ID: 19052

Assessment Status Assessment Process Complete
HTA ID 19052
Drug Polatuzumab vedotin
Brand Polivy®
Indication In combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).
Assessment Process
Rapid review commissioned 03/12/2019
Rapid review completed 27/01/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/02/2020
Pre-submission consultation with Applicant 31/03/2020
Full submission received from Applicant 10/07/2020
Preliminary review sent to Applicant 27/10/2020
NCPE assessment re-commenced 25/11/2020
Factual accuracy sent to Applicant 26/01/2021
NCPE assessment re-commenced 02/02/2021
NCPE assessment completed 16/02/2021
NCPE assessment outcome The NCPE recommends that polatuzumab vedotin (Polivy®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations December 2021.